|Articles|June 21, 2023
Buy vs. Build: Bioanalytical lab
Author(s) Pyxant
With so many outsourcing/insourcing options across drug development workflows, pharmaceutical companies are faced with finding the right partner to fit the needs of their unique molecule. There are criteria to consider when outweighing the benefits and risks associated with buying or building a bioanalytical lab.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
FAQ: FDA’s Shifts in Pharma Regulation and Strategy in 2025
2
EMA Calls New EU Pharma Legislation Most Significant in Two Decades
3
FDA’s CNPV Pilot Gives First Approval to Antibiotic for Pneumonia and Sinusitis
4
European Parliament Revamps Pharmaceutical Policy Framework
5
